hepatocellular carcinoma (HCC) - Articles and news items

SIRT is better tolerated than sorafenib, but doesn’t increase overall survival in HCC

Industry news / 28 April 2017 / Niamh Marriott, Junior Editor

Results of the SARAH trial demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179)…

BTG receives CE mark certification for radiopaque drug-eluting bead

Industry news / 6 April 2017 / Niamh Marriott, Junior Editor

BTG has received Class III CE Mark certification for DC Bead LUMI, the first commercially available radiopaque drug-eluting bead…

FDA grants priority review for Bayer’s liver cancer treatment

Industry news / 4 January 2017 / Niamh Louise Marriott, Digital Editor

The application is based on data from the placebo-controlled Phase III trial which investigated the drug as a second line treatment…

RedHill Biopharma commences Phase II hepatocellular carcinoma study

Industry news / 5 October 2016 / Niamh Louise Marriott, Digital Content Producer

RedHill Biopharma, will shortly commence a study evaluating yeliva (ABC294640) in patients with advanced hepatocellular carcinoma (HCC), pending final…

Regorafenib increases overall survival in hepatocellular carcinoma study

Industry news / 29 June 2016 / Victoria White, Digital Content Producer

Results from the Phase III RESORCE trial investigating Bayer’s regorafenib in patients with unresectable hepatocellular carcinoma have been announced…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+